What is the difference between GHRP-2 and GHRP-6?

GHRP-2 is classified as: Synthetic growth hormone secretagogue; ghrelin receptor (GHS-R1a) agonist; growth hormone-releasing peptide (GHRP). GHRP-6 is classified as: Synthetic growth hormone secretagogue; ghrelin receptor (GHS-R1a) agonist; first-described growth hormone-releasing hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys). GHRP-2 is investigational and is not an approved medicine. GHRP-6 is investigational and is not an approved medicine.

Is GHRP-2 or GHRP-6 approved?

GHRP-2 is investigational and is not an approved medicine. GHRP-6 is investigational and is not an approved medicine. Regulatory status by region is set out in the table above.

How much clinical trial evidence is tracked for GHRP-2 and GHRP-6?

Peptide Science Daily tracks 0 registered clinical trials for GHRP-2 (evidence grade C) and 40 for GHRP-6 (evidence grade C).

Compound comparison

GHRP-2 vs GHRP-6

This page sets GHRP-2 and GHRP-6 side by side using the data recorded on Peptide Science Daily: drug class, mechanism of action, regulatory status by region, the evidence grade assigned here, and the number of clinical trials tracked. It is a neutral, factual comparison and does not rank either compound or recommend one over the other.

Side-by-side comparison

Class: GHRP-2
Synthetic growth hormone secretagogue; ghrelin receptor (GHS-R1a) agonist; growth hormone-releasing peptide (GHRP)
GHRP-6
Synthetic growth hormone secretagogue; ghrelin receptor (GHS-R1a) agonist; first-described growth hormone-releasing hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys)
Mechanism: GHRP-2
In plain terms, GHRP-2 mimics the hunger hormone ghrelin to prompt the pituitary to release growth hormone.
GHRP-6
In plain terms, GHRP-6 acts like the hunger hormone ghrelin, prompting the pituitary to release growth hormone and increasing appetite.
United States (FDA): GHRP-2
Not approved for any indication; an unapproved growth hormone secretagogue with no marketed product.
GHRP-6
Not approved for any indication; an unapproved growth hormone secretagogue with no marketed product.
European Union (EMA): GHRP-2
No EMA marketing authorisation; not an approved medicine in the EU.
GHRP-6
No EMA marketing authorisation; not an approved medicine in the EU.
Australia (TGA): GHRP-2
Not on the Australian Register of Therapeutic Goods (ARTG); an unapproved substance with no registered product.
GHRP-6
Not on the Australian Register of Therapeutic Goods (ARTG); an unapproved substance with no registered product.
WADA: GHRP-2
Prohibited at all times under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics); growth hormone secretagogues including GHRP-2 are explicitly covered.
GHRP-6
Prohibited at all times under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics); growth hormone secretagogues including GHRP-6 are explicitly covered.
Japan (PMDA): GHRP-2
Approved as a diagnostic agent (pralmorelin) used to evaluate growth hormone secretory capacity; not approved as a therapeutic treatment.
GHRP-6
Not recorded
Evidence grade: GHRP-2
C
GHRP-6
C
Tracked clinical trials: GHRP-2
0
GHRP-6
40
Full profile: GHRP-2
GHRP-2 profile
GHRP-6
GHRP-6 profile

Comparison of GHRP-2 and GHRP-6 by class, mechanism, regulatory status by region, evidence grade, and number of tracked clinical trials.
Attribute	GHRP-2	GHRP-6
Class	Synthetic growth hormone secretagogue; ghrelin receptor (GHS-R1a) agonist; growth hormone-releasing peptide (GHRP)	Synthetic growth hormone secretagogue; ghrelin receptor (GHS-R1a) agonist; first-described growth hormone-releasing hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys)
Mechanism	In plain terms, GHRP-2 mimics the hunger hormone ghrelin to prompt the pituitary to release growth hormone.	In plain terms, GHRP-6 acts like the hunger hormone ghrelin, prompting the pituitary to release growth hormone and increasing appetite.
United States (FDA)	Not approved for any indication; an unapproved growth hormone secretagogue with no marketed product.	Not approved for any indication; an unapproved growth hormone secretagogue with no marketed product.
European Union (EMA)	No EMA marketing authorisation; not an approved medicine in the EU.	No EMA marketing authorisation; not an approved medicine in the EU.
Australia (TGA)	Not on the Australian Register of Therapeutic Goods (ARTG); an unapproved substance with no registered product.	Not on the Australian Register of Therapeutic Goods (ARTG); an unapproved substance with no registered product.
WADA	Prohibited at all times under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics); growth hormone secretagogues including GHRP-2 are explicitly covered.	Prohibited at all times under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics); growth hormone secretagogues including GHRP-6 are explicitly covered.
Japan (PMDA)	Approved as a diagnostic agent (pralmorelin) used to evaluate growth hormone secretory capacity; not approved as a therapeutic treatment.	Not recorded
Evidence grade	C	C
Tracked clinical trials	0	40
Full profile	GHRP-2 profile	GHRP-6 profile

Common questions

What is the difference between GHRP-2 and GHRP-6?: GHRP-2 is classified as: Synthetic growth hormone secretagogue; ghrelin receptor (GHS-R1a) agonist; growth hormone-releasing peptide (GHRP). GHRP-6 is classified as: Synthetic growth hormone secretagogue; ghrelin receptor (GHS-R1a) agonist; first-described growth hormone-releasing hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys). GHRP-2 is investigational and is not an approved medicine. GHRP-6 is investigational and is not an approved medicine.
Is GHRP-2 or GHRP-6 approved?: GHRP-2 is investigational and is not an approved medicine. GHRP-6 is investigational and is not an approved medicine. Regulatory status by region is set out in the table above.
How much clinical trial evidence is tracked for GHRP-2 and GHRP-6?: Peptide Science Daily tracks 0 registered clinical trials for GHRP-2 (evidence grade C) and 40 for GHRP-6 (evidence grade C).